An evidence-based systematic review on medical therapies for inflammatory bowel disease

American Journal of Gastroenterology

Volumn 106, Issue SUPPL. 1, 2011, Pages

  Talley, Nicholas J ^a   Abreu, Maria T ^b   Achkar, Jean Paul ^c   Bernstein, Charles N ^d   Dubinsky, Marla C ^e   Hanauer, Stephen B ^f   Kane, Sunanda V ^g   Sandborn, William J ^h   Ullman, Thomas A ⁱ   Moayyedi, Paul ^j  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Cedars Sinai MedicalCenter   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g Mayo Clinic   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL FACTOR; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; ENTERITIS; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; EDUCATION, MEDICAL, CONTINUING; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; WORLD HEALTH;

EID: 79953805710     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.58     Document Type: Article

References (320)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
2. Casellas F, Lopez-Vivancos J, Badia X et al. Influence of inflammatory bowel disease on diff erent dimensions of quality of life. Eur J Gastroenterol Hepatol 2001; 13: 567-72. (Pubitemid 32466261)
3. Graff LA, Walker JR, Clara I et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol 2009; 104: 2959-69.
4. Sirois FM. Psychological adjustment to inflammatory bowel disease: the importance of considering disease activity. Am J Gastroenterol 2009; 104: 2970-2.
5. Sonnenberg A, Chang J. Time trends of physician visits for Crohn ' s disease and ulcerative colitis in the United State, 1960-2006. Inflamm Bowel Dis 2008; 14: 249-52. (Pubitemid 351288047)
6. Sonnenberg A. Hospitalization for inflammatory bowel disease in the United States between 1970 and 2004. J Clin Gastroenterol 2009; 43: 297-300.
7. Kappelman MD, Rifas-Shiman SL, Porter C et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 1907-13.
8. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
9. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
10. Steinhart AH, Ewe K, Griffi ths AM et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003, Issue 4. Art. No.: CD000301. DOI: 10.1002/14651858.CD000301.
11. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn ' s disease. Cochrane Database Syst Rev 2003, Issue 4. Art. No.: CD003574. DOI: 10.1002/14651858.CD003574.pub2.
12. Kappelman MD, Rifas-Shiman SL, Kleinman K et al. Th e prevalence and geographic distribution of Crohn ' s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9. (Pubitemid 350181588)
13. Herrington LJ, Liu L, Lewis JD et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol 2008; 103: 1998-2006.
14. Loft us CG, Lofus EV, Harmsen WS et al. Update on the incidence and prevalence of Crohn ' s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13: 254-61. (Pubitemid 46465905)
15. Edouard A, Paillaud M, Merle S et al. Incidence of inflammatory bowel disease in the French West Indies (1997-1999). Gastroenterol Clin Biol 2005; 29: 779-83. (Pubitemid 41411356)
16. Abdul-Baki H, ElHajj I, El-Zahabi LM et al. Clinical epidemiology of in- flammatory bowel disease in Lebanon. Inflamm Bowel Dis 2007; 13: 475-80. (Pubitemid 46668254)
17. Shivananda S, Lennard-Jones J, Logan R et al. Incidence of inflammatory bowel disease across Europe: is there a diff erence between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-7. (Pubitemid 26426470)
18. Al-Ghamdi AS, Al-Mofleh IA, Al-Rashed RS et al. Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh. World J Gastroenterol 2004; 10: 1341-4. (Pubitemid 39162444)
19. Edwards CN, Griffi th SG, Hennis AJ et al. Inflammatory bowel disease: incidence, prevalence, and disease characteristics in Barbados, West Indies. Inflamm Bowel Dis 2008; 14: 1419-24.
20. Bernstein CN, Wajda A, Svenson LW et al. Th e epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006; 101: 1559-68. (Pubitemid 43980630)
21. Appleyard CB, Hernandez G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm Bowel Dis 2004; 10: 106-11. (Pubitemid 38332169)
22. Bjornsson S, Johannsson JH. Inflammatory bowel disease in Iceland, 1990 - 1994: a prospective, nationwide, epidemiological study. Eur J Gastroenterol Hepatol 2000; 12: 31-8. (Pubitemid 30072102)
23. Pavlovic-Calic N, Salkic NN, Gegic A et al. Crohn's disease in Tuzla region of Bosnia and Herzegovina: a 12 year study (1995-2006). Int J Colorectal Dis 2008; 23: 957-64.
24. Economou M, Filis G, Tsianou Z et al. Crohn's disease incidence evolution in North-western Greece is not associated with alteration of NOD2/ CARD15 variants. World J Gastroenterol 2007; 13: 5116-20. (Pubitemid 47527349)
25. Gearry RB, Richardson A, Frampton CMA et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006; 12: 936-43. (Pubitemid 44498282)
26. Gheorghe C, Pascu O, Gheorghe L et al. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. Eur J Gastroenterol Hepatol 2004; 16: 1153-9. (Pubitemid 39488787)
27. Jacobson BA, Fallingborg J, Rasmussen HH et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population- based study, 1978-2002. Eur J Gastroenterol Hepatol 2006; 18: 601-6. (Pubitemid 43804642)
28. Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J 2006; 82: 332-7. (Pubitemid 43780664)
29. Lakatos L, Mester G, Erdelyi Z et al. Striking elevation in incidence and prevalence of inflammatory bowel disease of western Hungary between 1977-2001. World J Gastroenterol 2004; 10: 404-9. (Pubitemid 38208096)
30. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World Journal of Gastroenterology 2006; 12: 75-81. (Pubitemid 43126087)
31. Leong RWL, Lau JY, Sung JJY. Th e epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis 2004; 10: 646-51. (Pubitemid 39276475)
32. Nerich V, Monnet E, Louafi S et al. Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis 2006; 12: 218-26.
33. Rodriguez LAG, Gonzalez-Perez A, Johansson S et al. Risk factors for inflammatory disease in the general population. Aliment Pharmacol Th er 2005; 22: 309-15. (Pubitemid 41207460)
34. Ott C, Obermeier F, Th ieler S et al. Th e incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective populationbased study. Eur J Gastroenterol Hepatol 2008; 20: 917-23.
35. Rodrigo L, Riestra S, Nino P et al. A population-based study on the incidence of inflammatory bowel disease in Oviedo (Northern Spain). Rev Esp Enferm Dig (Madrid) 2004; 96: 296-304. (Pubitemid 38979198)
36. Russsel MGVM, Dorant E, Volovics A, et al., Th e South Limburg IBD Study Group. High incidence of inflammatory bowel disease in Th e Netherlands. Results of a prospective study. Dis Colon Rectum 1998; 41: 33-40. (Pubitemid 28044873)
37. Salupere R. Inflammatory bowel disease in Estonia: a prospective epidemiologic study 1993-1998. World J Gastroenterol 2001; 7: 387-8. (Pubitemid 32586525)
38. Th ia KT, Loft us EV, Sandborn WJ et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-82.
39. Latour P, Belaiche J, Louis E. Incidence of inflammatory bowel disease in the province of Liege (Belgium). Acta Gastroenterol Belg 1996; 59: 3-6.
40. Ranzi T, Bodini P, Zambelli A et al. Epidemiological aspects of inflammatory bowel disease in a north Italian population: a 4-year prospective study. Eur J Gastroenterol Hepatol 1996; 8: 657-61. (Pubitemid 26241594)
41. Victoria CR, Sassaki LY, Nunes HR. Incidence and prevalence rates of inflammatory bowel diseases, in Midwestern of Sao Paulo State, Brazil. Arq Gastroenterol 2009; 46: 20-5.
42. Yang SK, Yun S, Kim JH et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong District, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008; 14: 542-9. (Pubitemid 351571835)
43. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000; 43 (Suppl): 885-93.
44. Zheng JJ, Zhu XS, Huangfu Z et al. Crohn's disease in mainland China: a systematic analysis of 50 years of research. Chin J Dig Dis 2005; 6: 175-81.
45. Tezel A, Dokmeci G, Eskiocak M et al. Epidemiological features of ulcerative colitis in Trakya, Turkey. J Int Med Res 2003; 31: 141-8. (Pubitemid 36553313)
46. Sood A, Midha V, Sood N et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003; 52: 1587-90. (Pubitemid 37363442)
47. Radhakrishnan S, Zubaidi G, Daniel M et al. Ulcerative colitis in Oman. A prospective study of the incidence and disease pattern from 1987 to 1994. Digestion 1997; 58: 266-70. (Pubitemid 27270192)
48. Gunesh S, Th omas GAO, Williams GT et al. Th e incidence of Crohn's disease in Cardiff over the last 75 years: an update for 1996-2005. Aliment Pharmacol Th er 2008; 27: 211-9.
49. Loft us EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 1-20. (Pubitemid 34733030)
50. Cornish JA, Tan E, Simillis C et al. Th e risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2394-400.
51. Hou JK, El-Serag H, Th irumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009; 104: 2100-9.
52. Mahid SS, Minor KS, Soto RE et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clinic Proc 2006; 81: 1462-71. (Pubitemid 44687433)
53. Jones DT, Osterman MT, Bewtra M et al. Passive smoking and inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2382-93.
54. Bernstein CN, Rawsthorne P, Cheang M et al. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol 2006; 101: 993-1002. (Pubitemid 43725312)
55. Kaplan GG, Jackson T, Sands BE et al. The risk of developing Crohn ' s disease aft er an appendectomy: a meta-analysis. Am J Gastroenterol 2008; 103: 2925-31.
56. Koutroubakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol 2000; 95: 171-6. (Pubitemid 30041554)
57. Orholm M, Binder V, S ø rensen TI et al. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000; 35: 1075-81.
58. Halfvarson J, Jess T, Magnuson A et al. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis 2006; 12: 925-33. (Pubitemid 44498280)
59. Economou M, Trikalinos TA, Loizou KT et al. Diff erential eff ects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99: 2393-404. (Pubitemid 40039371)
60. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004; 4: 478-85. (Pubitemid 38745559)
61. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006; 130: 1588-94. (Pubitemid 43668828)
62. Gradel KO, Nielsen HL, Sch ø nheyder HC et al. Increased short- and longterm risk of inflammatory bowel disease aft er salmonella or campylobacter gastroenteritis. Gastroenterology 2009; 137: 495-501.
63. Qin J, Li R, Raes J, et al., MetaHIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
64. Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 205-11. (Pubitemid 43117279)
65. Riordan AM, Ruxton CH, Hunter JO. A review of associations between Crohn ' s disease and consumption of sugars. Eur J Clin Nutr 1998; 52: 229-38. (Pubitemid 28159617)
66. Geerling BJ, Dagnelie PC, Badart-Smook A et al. Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol 2000; 95: 1008-13. (Pubitemid 30196738)
67. Sakamoto N, Kono S, Wakai K et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005; 11: 154-63. (Pubitemid 40711220)
68. Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992; 3: 47-52.
69. Jantchou P, Morois S, Clavel-Chapelon F et al. Animal protein intake and risk of inflammatory bowel disease: The E3N Prospective Study. Am J Gastroenterol 2010; 105: 2195-201.
70. Strachan DP. Hay fever, hygiene, and the household size. BMJ 1989; 299: 1259-60. (Pubitemid 19280051)
71. Wells RW, Blennerhassett MG. The increasing prevalence of Crohn's disease in industrialized societies: the price of progress? Can J Gastroenterol 2005; 19: 89-95. (Pubitemid 40392722)
72. Gearry RB, Richardson AK, Frampton CM et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010; 25: 325-33.
73. Green C, Elliott L, Beaudoin C et al. A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol 2006; 164: 615-23. (Pubitemid 44453488)
74. Klement E, Lysy J, Hoshen M et al. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am J Gastroenterol 2008; 103: 1775-82.
75. Sincic BM, Vucelic B, Persic M et al. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: a prospective population-based study. Scand J Gastroenterol 2006; 41: 437-44. (Pubitemid 43675410)
76. Lashner BA, Loft us EV Jr. True or false? The hygiene hypothesis for Crohn ' s disease. Am J Gastroenterol 2008; 10: 1003-4.
77. Moayyedi P. Clues to the etiology of inflammatory bowel disease-a return to John Snow? Am J Epidemiol 2006; 164: 624-6. (Pubitemid 44453489)
78. Loft us EV, Feagan BG, Colombel JF et al. Eff ects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn ' s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008; 103: 3132-41.
79. Feagan BG, Sandborn WJ, Hass S et al. Health-related quality of life during natalizumab maintenance therapy for Crohn ' s disease. Am J Gastroenterol 2007; 102: 2737-46. (Pubitemid 350179328)
80. Timmer A, McDonald JWD, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, Issue 1. Art. No.: CD000478. DOI: 10.1002/14651858. CD000478.pub2.
81. Sandborn WJ, Sutherland LR, Pearson D et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn ' s disease. Cochrane Database Syst Rev 1998, Issue 3. Art. No.: CD000545. DOI: 10.1002/14651858. CD000545.
82. Prefontaine E, Sutherland LR, MacDonald JK et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn ' s disease. Cochrane Database Syst Rev 2009, Issue 1. Art. No.: CD000067. DOI: 10.1002/14651858. CD000067.pub2.
83. Seow CH, Benchimol EI, Griffi ths AM et al. Budesonide for induction of remission in Crohn ' s disease. Cochrane Database Syst Rev 2008, Issue 3. Art. No.: CD000296. DOI: 10.1002/14651858.CD000296.pub3.
84. Benchimol EI, Seow CH, Otley AR et al. Budesonide for maintenance of remission in Crohn ' s disease. Cochrane Database Syst Rev 2009, Issue 1. Art. No.: CD002913. DOI: 10.1002/14651858.CD002913.pub2.
85. Shibolet O, Regushevskaya E, Brezis M et al. Cyclosporin A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005, Issue 1. Art. No.: CD004277. DOI: 10.1002/14651858.CD004277.pub2.
86. McDonald JWD, Feagan BG, Jewell DP et al. Cyclosporin for induction of remission in Crohn ' s disease. Cochrane Database Syst Rev 2005, Issue 2. Art. No.: CD000297. DOI: 10.1002/14651858.CD000297.pub2.
87. Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn ' s disease. Cochrane Database Syst Rev 2004, Issue 4. Art. No.: CD003459. DOI: 10.1002/14651858.CD003459.pub2.
88. Chande N, MacDonald JK, McDonald JWD. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, Issue 4. Art. No.: CD006618. DOI: 10.1002/14651858.CD006618.pub2. (Pubitemid 351805294)
89. MacDonald JK, McDonald JWD. Natalizumab for induction of remission in Crohn ' s disease. Cochrane Database Syst Rev 2007, Issue 1. Art. No.: CD006097. DOI: 10.1002/14651858.CD006097.pub2. (Pubitemid 351835441)
90. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD000543. DOI: 10.1002/14651858.CD000543.pub2.
91. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn ' s disease. Cochrane Database Syst Rev 2005, Issue 1. Art. No.: CD003715. DOI: 10.1002/14651858.CD003715.pub2.
92. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD000544. DOI: 10.1002/14651858.CD000544.pub2.
93. Benchimol EI, Seow CH, Steinhart AH et al. Traditional corticosteroids for induction of remission in Crohn ' s disease. Cochrane Database Syst Rev 2008, Issue 2. Art. No.: CD006792. DOI: 10.1002/14651858.CD006792. pub2.
94. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn ' s disease. Cochrane Database Syst Rev 2008, Issue .Art. No.: CD006893. DOI: 10.1002/14651858.CD006893 (Pubitemid 351807740)
95. Lawson MM, Th omas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, Issue 3. Art. No.: CD005112. DOI: 10.1002/14651858.CD005112.pub2.
96. Baumgart DC, MacDonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008, Issue 3. Art. No.: CD007216. DOI: 10.1002/14651858.CD007216.
97. Ford AC, Guyatt GH, Talley NJ et al. Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol 2010; 105: 280-8.
98. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl 1): S1-S35.
99. Ford AC, Achkar JP, Khan KJ et al. Effi cacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-616.
100. Ford AC, Kane SV, Khan KJ et al. Effi cacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. American Journal of Gastroenterology 2011; 106: 617-29.
101. Ford AC, Bernstein CN, Khan KJ et al. Glucocorticosteroide therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 590-99.
102. Khan KJ, Dubinsky MC, Ford AC et al. Effi cacy of immunosuppressive therapy in inflammatory bowel disease: systematic review and meta-analysis . Am J Gastroenterology 2011; 106: 630-42.
103. Ford AC, Sandborn WJ, Khan KJ et al. Effi cacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-59.
104. Khan KJ, Ullman TA, Ford AC et al. Antibiotic therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-73.
105. D ' Haens GR, Fedorak R, Lemann M et al. Endpoints for clinical trials evaluating disease modifi cation and structural damage in adults with Crohn ' s disease. Inflamm Bowel Dis 2009; 15: 1599-604.
106. D ' Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and effi cacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
107. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions (ISBN 978-0470057964) by John Wiley & Sons Ltd. Chichester, UK: The Atrium.
108. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
109. Egger M, Davey-Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34. (Pubitemid 27387172)
110. Falck-Ytter Y, Kunz R, Guyatt GH et al. How strong is the evidence? Am J Gastroenterol 2008; 103: 1334-8. (Pubitemid 351813917)
111. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 160-70. (Pubitemid 46416252)
112. Svartz N. Salazopyrin: a new sulfanilamide preparation. Acta Med Scand 1942; 110: 577-98.
113. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 310: 892-5.
114. Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis. What are the implications of the new formulations. J Clin Gastroenterol 2008; 42: 338-44. (Pubitemid 351450616)
115. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remission in ulcerative colitis. Aliment Pharmacol Ther 2006; 24 (Suppl 3): 37-40. (Pubitemid 44326418)
116. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Therap 2006; 24 (Suppl 1): 2-9. (Pubitemid 44267773)
117. Sandborn WJ, Hanauer SB. The pharmacokinetic profi les of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Therap 2003; 17: 29-42. (Pubitemid 36140432)
118. Loft us EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Therap 2004; 19: 179-89. (Pubitemid 38174887)
119. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13: 629-38. (Pubitemid 46799647)
120. Baron JH, Connell AM, Lennard-Jones JE et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; 1: 1094-6.
121. Dick AP, Grayson MJ, Carpenter RG et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5: 437-42.
122. Hetzel DJ, Shearman DJC, Bochner F et al. Azodisalicylate (olsalazine) in the treatment of active ulcerative colitis. A placebo controlled trial and assessment of drug disposition. J Gastroenterol Hepatol 1986; 1: 257-66.
123. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9. (Pubitemid 18010466)
124. Miner P, Nostrant T, Wruble L et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology 1991; 100 (Suppl): A231.
125. Sninsky CA, Cort DH, Shanahan F et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. Ann Intern Med 1991; 115: 350-5.
126. Hanauer S, Schwartz J, Robinson M et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 1188-97. (Pubitemid 23219711)
127. Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75. (Pubitemid 46108735)
128. Lichtenstein GR, Kamm MA, Boddu P et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5 : 95-102. (Pubitemid 46096842)
129. Scherl EJ, Pruitt R, Gordon GL et al. Safety and effi cacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2009; 104: 1452-9.
130. Ito H, Iida M, Matsumoto T et al. Direct comparison of two diff erent mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind randomized study. Inflamm Bowel Dis 2010; 16: 1567-74.
131. Miglioli M, Bianchi Porro G, Brunetti G et al. Delayed release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol 1990; 2: 229-34. (Pubitemid 20272950)
132. Hanauer SB, Sandborn WJ, Kornbluth A et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85.
133. D'Haens G, Hommes D, Engels L et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006; 24: 1087-97. (Pubitemid 44386534)
134. Hanauer SB, Sandborn WJ, Dallaire C et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007; 21: 827-34. (Pubitemid 351255702)
135. Sandborn WJ, Regula J, Feagan BG et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is Effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-43.
136. Misiewicz JJ, Lennard-Jones JE, Connell AM et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; 185: 187.
137. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) . Gut 1973; 14: 923-6.
138. Riis P, Anthonisen P, Wulff HR et al. The prophylactic Effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A doubleblind trial on patients asymptomatic for one year. Scand J Gastroenterol 1973; 8: 71-4.
139. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 1986; 90: 1024-30. (Pubitemid 16124782)
140. Lauritsen K, Staerk Laursen L, Bukhave K et al. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988; 29: 1316-21.
141. Wright JP, O'Keefe EA, Cuming L et al. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 1993; 38: 1837-42. (Pubitemid 23311935)
142. Miner P, Hanauer S, Robinson M et al. Safety and efficacy of controlledrelease mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995; 40: 296-304.
143. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. Ann Intern Med 1996; 124: 204-11.
144. Hawkey CJ, Dube LM, Rountree LV et al. A trial of zileuton vs. mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997; 112: 718-24. (Pubitemid 27113796)
145. Ardizzone S, Petrillo M, Imbesi V et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999; 13: 373-9. (Pubitemid 29142047)
146. Lichtenstein GR, Gordon GL, Zakko S et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6- month placebo-controlled trial. Aliment Pharmacol Ther 2010; 32: 990-9.
147. Azad Khan AK, Howes DT, Piris J et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980; 21: 232-40. (Pubitemid 10082935)
148. Green JRB, Swan CHJ, Rowlinson A et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992; 6: 647-52.
149. Travis SPL, Tysk C, de Silva HJ et al. Optimum dose of olsalazine for maintaining remission of ulcerative colitis. Gut 1994; 35: 1282-6. (Pubitemid 24277345)
150. Fockens P, Mulder CJJ, Tytgat GNJ et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 1025-30. (Pubitemid 26014456)
151. Kruis W, Schreiber S, Theuer D et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001; 49: 783-9. (Pubitemid 33096035)
152. Paoluzi OA, Iacopini F, Pica R et al. Comparison of two diff erent daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 1111-9. (Pubitemid 40646537)
153. Kruis W, Jonaitis L, Pokrotniets J et al. Randomised clinical trial: a comparative dose-fi nding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-22.
154. Dr Stephen B. Hanauer, Crohn's II study: personal communication.
155. Summers RW, Switz DM, Sessions JT Jr et al. National cooperative Crohn ' s disease study: results of drug treatment. Gastroenterology 1979; 77: 847-69. (Pubitemid 9242048)
156. Rasmussen SN, Lauritsen K, Tage-Jensen U et al. 5-Aminosalicylic acid in the treatment of Crohn ' s disease: a 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987; 22: 877-83. (Pubitemid 18041645)
157. Singleton JW, Hanauer SB, Gitnick GL et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993; 104: 1293-301. (Pubitemid 23235401)
158. Tremaine WJ, Schroeder KW, Jarrison JM et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 278-82. (Pubitemid 24371047)
159. Malchow M, Ewe K, Brandes JW et al. European cooperative Crohn's disease
160. Hanauer SB, Stromberg U. Oral Penasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo controlled trials. Clin Gastroenterol Hepatol 2004; 2: 379-88. (Pubitemid 38561234)
161. Prantera C, Pallone F, Brunetti G et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363-8.
162. Th omson ABR, Wright JP, Vatn M et al. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995; 9: 673-83. (Pubitemid 26042105)
163. Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. Gut 1977; 18: 69-72.
164. Wellmann W, Schroder U. New oral preparations for maintenance therapy in Crohn's disease. Can J Gastroenterol 1988; 2 (Suppl A): 71A-2A.
165. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid vs. placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4: 55-64.
166. Gendre J-P, Mary J-Y, Florent C et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435-9. (Pubitemid 23033415)
167. Arber N, Odes S, Fireman Z et al. A controlled double blind multicenter study of the Effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995; 20: 203-6.
168. Modigliani R, Colombel J-F, Dupas J-L et al. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance. Gastroenterology 1996; 110: 688-93. (Pubitemid 26075447)
169. De Franchis R, Omodei P, Ranzi T et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 1997; 11: 845-52. (Pubitemid 27445669)
170. Sutherland LR, Martin F, Bailey RJ et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. Gastroenterology 1997; 112: 1069-77. (Pubitemid 27157516)
171. Mahmud N, Kamm MA, Dupas J-L et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001; 49: 552-6. (Pubitemid 32896987)
172. Bondesen S, and the Danish 5-ASA Group. Mesalazine (Pentasa) as prophylaxis in Crohn's disease. A multicenter, controlled trial. Scand J Gastroenterol 1991; 26: 68.
173. Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our experience. Int J Clin Pharm Res 1994; 14: 133-8.
174. Singleton JW, Summers RW, Kern F Jr et al. A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979; 77: 887-97. (Pubitemid 9242051)
175. Hench PS, Kendall EC, Slocumb CH et al. The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (Compound E) on the acute phase of rheumatic fever; preliminary report. Mayo Clin Proc 1949; 24: 277-97.
176. Saenger AK. Discovery of the wonder drug: from cows to cortisone. Clin Chem 2010; 56: 1349-50.
177. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-8.
178. Toruner M, Loft us EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36. (Pubitemid 351451967)
179. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3: 81-92. (Pubitemid 36705487)
180. Marehbian J, Arrighi HM, Hass S et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009; 104: 2524-33.
181. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
182. Irving PM, Gearry RB, Sparrow MP et al. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Therap 2007; 26: 313-29. (Pubitemid 47063143)
183. Seow CH, Benchimol EI, Steinhart AH et al. Budesonide for Crohn's disease. Expert Opin Drug Metab Toxicol 2009; 5: 971-9.
184. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57: 267-79. (Pubitemid 39536102)
185. Goulding NJ. The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus. Curr Opin Pharmacol 2004; 4: 629-36. (Pubitemid 40267879)
186. Hayashi R, Wada H, Ito K et al. effects of glucocorticoids on gene transcription . Eur J Pharmacol 2004; 500: 51-62. (Pubitemid 39303996)
187. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003; 24: 488-522. (Pubitemid 37059110)
188. Kagoshima M, Ito K, Cosio B et al. Glucocorticoid suppression of nuclear factor-kappa B: a role for histone modifi cations. Biochem Soc Trans 2003; 31: 60-5. (Pubitemid 36241397)
189. Buttgereit F, Saag KG, Cutolo M et al. The molecular basis for the Effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 2005; 34: 14-21. (Pubitemid 40445053)
190. Angus P, Snook JA, Reid M et al. Oral fluticasone propionate in active distal ulcerative colitis. Gut 1992; 33: 711-4.
191. Bossa F, Latiano A, Rossi L et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008; 103: 2509-16.
192. Lennard-Jones JE, Longmore AJ, Newell AC et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 217-22.
193. Rizzello F, Gionchetti P, Galeazzi R et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-fi nding study. Adv Ther 2001; 18: 261-71. (Pubitemid 34117282)
194. Bossa F, Fiorella S, Caruso N et al. Continuous infusion vs. bolus administration of steroids in severe attacks of ulcerative colitis: a randomized double blind trial. Am J Gastroenterol 2007; 102: 601-8. (Pubitemid 46328134)
195. Greenberg GR, Feagan BG, Martin F et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-41. (Pubitemid 24289710)
196. Tremaine WJ, Hanauer SB, Katz S et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002; 97: 1748-54. (Pubitemid 34761401)
197. Bar-Meir S, Chowers Y, Lavy A et al. Budesonide vs. prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115: 835-40. (Pubitemid 28452930)
198. Campieri M, Ferguson A, Doe W et al. Oral budesonide is as Effective as oral prednisolone in active Crohn's disease. Gut 1997; 41: 209-14. (Pubitemid 27395924)
199. Gross V, Andus T, Caesar I et al. Oral pH-modifi ed release budesonide vs. 6-methylprednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8: 905-9. (Pubitemid 26319395)
200. Rutgeerts P, Lofb erg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5. (Pubitemid 24289711)
201. Tursi A, Giorgetti GM, Brandimarte G et al. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. Med Sci Monitor 2006; 12: I29-32.
202. Van Ierssel AJ, Van der Sluys Veer A, Verspaget HW et al. Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease. Aliment Pharmacol Ther 1995; 9: 173-8.
203. Ferguson A, Campieri M, Doe W et al. Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Therap 1998; 12: 175-83. (Pubitemid 28059985)
204. Greenberg GR, Feagan BG, Martin F et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110: 45-51. (Pubitemid 26021603)
205. Gross V, Andus T, Ecker KW et al. Low dose oral pH modifi ed release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut 1998; 42: 493-6. (Pubitemid 28186564)
206. Hanauer S, Sandborn WJ, Persson A et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Therap 2005; 21: 363-71. (Pubitemid 40320545)
207. Lofb erg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996; 39: 82-6. (Pubitemid 26239111)
208. Cortot A, Colombel J-F, Rutgeerts P et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 2001; 48: 186-90. (Pubitemid 32141841)
209. Toledo-Pereyra LH, Toledo AH. 1954. J Invest Surg 2005; 18: 285-90.
210. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: The older drugs. Am J Therap 2001; 8: 123-43. (Pubitemid 33753526)
211. Bean RHD. The treatment of chronic ulcerative colitis with 6-mercaptopurine . Med J Aust 1962; 2: 592-3.
212. Bean RHD. Treatment of ulcerative colitis with antimetabolites. Br Med J 1966; 1: 1081-4.
213. Brooke BN, Hoff mann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet 1969; 2: 612-4.
214. Bowen GE, Irons GV Jr, Rhodes JD et al. Early experience with azathioprine in ulcerative colitis. JAMA 1966; 195: 166-70.
215. Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Therap 2005; 21: 307-19. (Pubitemid 40313935)
216. Fournier MR, Klein J, Minuk GY et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1620-6.
217. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: fi nal report on controlled therapeutic trial. Br Med J 1974; 4: 627-30.
218. Sood A, Midha V, Sood N et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19: 14-6. (Pubitemid 30048938)
219. Oren R, Arber N, Odes S et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-21. (Pubitemid 26134073)
220. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5. (Pubitemid 24188135)
221. Sandborn WJ, Colombel JF, Frankel M et al. Anti-CD3 antibody visilizumab is not Effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010; 59: 1485-92.
222. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 vs. 2 mg/kg intravenous cyclosporin in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31. (Pubitemid 37193449)
223. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporin vs. intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9. (Pubitemid 32322305)
224. Ogata H, Matsui T, Nakamura M et al. A randomized dose fi nding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-62. (Pubitemid 44277355)
225. Sood A, Kaushal V, Midha V et al. The benefi cial Effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-4. (Pubitemid 34495524)
226. Hawthorne AB, Logan RF, Hawkey CJ et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
227. Onuk MD, Kaymakoglu S, Demir K et al. Low-dose weekly methotrexate therapy in remission maintenance in ulcerative colitis [abstract]. Gut 1996; 39 (Suppl 3): A75.
228. Ewe K, Press AG, Singe CC et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-72. (Pubitemid 23213520)
229. Candy S, Wright J, Gerber M et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
230. Reinisch W, Panes J, Lemann M et al. A multicenter, randomized, doubleblind trial of everolimus vs. azathioprine and placebo to maintain steroidinduced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103: 2284-92.
231. Klein M, Binder HJ, Mitchell M et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66: 916-22.
232. Rhodes J, Beck P, Bainton D et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 1273-6.
233. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7. (Pubitemid 10125406)
234. Oren R, Moshkowitz M, Odes S et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-9.
235. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
236. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more effi cacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86-90.
237. Stange EF, Modigliani R, Pena AS et al. European trial of cyclosporin in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995; 109: 774-82.
238. Brynskov J, Freund L, Rasmussen SN et al. A placebo-controlled, doubleblind, randomized trial of cyclosporin therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845-50. (Pubitemid 19238615)
239. Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment of fi stulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125: 380-8. (Pubitemid 36929418)
240. Willoughby JM, Kumar PJ, Beckett J et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 944-6.
241. Lemann M, Mary JY, Colombel JF et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-8. (Pubitemid 40824692)
242. O'Donoghue DP, Dawson AM, Powell-Tuck J et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-7. (Pubitemid 9061740)
243. Vilien M, Dahlerup JF, Munck LK et al. Randomized controlled azathioprine withdrawal aft er more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Therap 2004; 19: 1147-52. (Pubitemid 38746257)
244. Rosenberg JL, Levin B, Wall AJ et al. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20: 721-6.
245. D'Haens GR, Noman M, Van Assche GA et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: a double-blind controlled randomized trial. Gastroenterology 2007; 132 (Suppl 2): A52.
246. Hanauer SB, Korelitz BI, Rutgeerts P et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-9. (Pubitemid 39208405)
247. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32. (Pubitemid 30341531)
248. Arora S, Katkov W, Cooley J et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepato-Gastroenterology 1999; 46: 1724-9. (Pubitemid 29366332)
249. Vilcek J. From IFN to TNF: a journey into realms of lore. Nat Immunol 2009; 10: 555-7.
250. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90. (Pubitemid 23360007)
251. Lichtenstein GR, Abreu MT, Cohen R et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-87. (Pubitemid 43374543)
252. Travis SP, Stange EF, Lemann M et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management . Gut 2006; 55 (Suppl 1): i16-35. (Pubitemid 43268291)
253. Hansen RA, Gartlehner G, Powell GE et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007; 5: 729-35.
254. Jones JL, Loft us EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007; 13: 1299-307. (Pubitemid 47597781)
255. Probert CJ, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998-1002. (Pubitemid 36765292)
256. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
257. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology 2005; 128: 1805-11. (Pubitemid 40824691)
258. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-8.
259. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
260. Lemann M, Mary J, Duclos B et al. Infliximab plus Azathioprine for steroid- dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
261. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 591; 130: 323-33.
262. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
263. Hibi T, Watanabe M, Camez A et al. efficacy and safety of adalimumab for the treatment of Japanese patients with moderately to severely active Crohn's disease: results from a randomized trial. Am J Gastroenterol 2008; ACG abstract 2008.
264. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18. (Pubitemid 41242673)
265. Winter TA, Wright J, Ghosh S et al. Intravenous CDP870, a PEGylated Fab ′fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Therap 2004; 20: 1337-46. (Pubitemid 40040081)
266. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. New Engl J Med 2007; 357: 228-38. (Pubitemid 47080387)
267. Sandborn W, Schreiber S, Feagan B et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebocontrolled trial. Am J Gastroenterol 2010; 105 (Suppl 1): S419.
268. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
269. Gordon FH, Lai CW, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268-74. (Pubitemid 32729374)
270. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. New Engl J Med 2003; 348: 24-32. (Pubitemid 36026343)
271. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. New Engl J Med 2005; 353: 1912-25. (Pubitemid 41565956)
272. Sands BE, Kozarek R, Spainhour J et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007; 13: 2-11. (Pubitemid 46080003)
273. Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007; 132: 1672-83. (Pubitemid 46695722)
274. Yousry TA, Major EO, Rysckewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl J Med 2006; 354: 924-33.
275. Cliff ord DB, De Luca A, Simpson DM et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-46.
276. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al., for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50. (Pubitemid 47080388)
277. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fi stulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. (Pubitemid 29205403)
278. Colombel J-F, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fi stulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
279. Rutgeerts P, D'Haens G, Targan S et al. efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9. (Pubitemid 29468216)
280. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
281. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
282. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9. (Pubitemid 47300424)
283. Clark M, Colombel JF, Feagan BC et al. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-39. (Pubitemid 47031141)
284. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-97.
285. Feagan BG, McDonald J, Ponich T et al. A randomized trial of methotrexate in combination with infliximab for treatment of Crohn's disease. Gastroenterology 2008; 135: 294.
286. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fi stulizing Crohn's disease. New Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
287. Rolfe VE, Fortun PJ, Hawkey CJ et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006, Issue 4, Art. No. CD004826.
288. Mallon P, McKay D, Kirk S et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, Issue 4, Art. No. CD005573.
289. Rahimi R, Nikfar S, Rahimi F et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Digest Dis Sci 2008; 53: 2524-31.
290. Colemont LJ, Pattyn SR, Michielssen PP et al. Acid-fast bacilli in Crohn's disease. Lancet 1988; 1: 294-5. (Pubitemid 18052276)
291. Feller M, Huwiler K, Stephan R et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and metaanalysis . Lancet Infect Dis 2007; 7: 607-13. (Pubitemid 47268226)
292. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis 2007; 44: 256-62. (Pubitemid 46079991)
293. Hugot JP, Alberti C, Berrebi D et al. Crohn's disease: the cold chain hypothesis. Lancet 2003; 362: 2012-5. (Pubitemid 37548429)
294. Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-21. (Pubitemid 39091889)
295. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis 1998; 4 : 29-39. (Pubitemid 128699834)
296. Mantzaris GJ, Hatzis A, Kontogiannis P et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-6. (Pubitemid 24020050)
297. Ohkusa T, Nomura T, Terai T et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005; 40 : 1334-42. (Pubitemid 41658733)
298. Ohkusa T, Kato K, Terao T et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010; 105: 1820-9.
299. Mantzaris GJ, Archavlis E, Christoforidis P et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92: 454-6. (Pubitemid 27108180)
300. Mantzaris GJ, Petraki K, Archavlis E et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-4. (Pubitemid 32681462)
301. Turunen UM, Farkkila MA, Hakala K et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebocontrolled study. Gastroenterology 1998; 115: 1072-8. (Pubitemid 28485596)
302. Burke DA, Axon ATR, Clayden SA et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Therap 1990; 4: 123-9. (Pubitemid 20300400)
303. Dickinson RJ, O'Connor HJ, Pinder I et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-4. (Pubitemid 16134465)
304. Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Digest Dis Sci 1999; 44: 1220-1. (Pubitemid 29297232)
305. Lobo AJ, Burke DA, Sobala GM et al. Oral tobramycin in ulcerative colitis: Effect on maintenance of remission. Aliment Pharmacol Therap 1993; 7: 155-8. (Pubitemid 23109461)
306. Prantera C, Kohn A, Mangiarotti R et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-8. (Pubitemid 24106215)
307. Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-9. (Pubitemid 46890859)
308. Steinhart AH, Feagan BG, Wong CJ et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40. (Pubitemid 34747523)
309. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn' s disease following therapy for mycobacterium paratuberculosis infection. Gastroenterology 1995; 108: A826.
310. Leiper K, Martin K, Ellis A et al. Clinical trial: randomized study of clarithromycin vs. placebo in active Crohn's disease. Aliment Pharmacol Therap 2008; 27: 1233-9. (Pubitemid 351697272)
311. Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 199; 32: 1071-5.
312. Arnold GL, Beaves MR, Pryjdun VO et al. Preliminary study of cipro- floxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-5. (Pubitemid 34130123)
313. Afdhal NH, Long A, Lennon J et al. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine vs. placebo. Dig Dis Sci 1991; 36: 449-53.
314. Prantera C, Lochs H, Campieri M et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebocontrolled trial with rifaximin. Aliment Pharmacol Ther 2006; 23 : 1117-25. (Pubitemid 43779351)
315. Prantera C, Lochs H, Giochetti P et al. Rifaximin-EIR (extended intestinal release) 400 mg tablets in the treatment of moderately active Crohn's disease: results of the international multicentre, randomised, double-blind, placebo-controlled trial RETIC-03. Gut 2010; 59 (Suppl III): A1.
316. West RL, van der Woude CJ, Hansen BE et al. Clinical and endosonographic Effect of ciprofloxacin on the treatment of perianal fi stulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Therap 2004; 20: 1329-36. (Pubitemid 40040080)
317. Maeda Y, Ng SC, Durdey P, et al., The Topical Metronidazole in Perianal Crohn's Study Group. Randomized clinical trial of metronidazole ointment vs. placebo in perianal Crohn's disease. Br J Surg 2010; 97: 1340-7.
318. Th ia KT, Mahadevan U, Feagan BG et al. Ciprofloxacin or metronidazole for the treatment of perianal fi stulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15: 17-24.
319. Peyrin-Biroulet L, Loft us EV Jr, Colombel JF et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-97.
320. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7. (Pubitemid 351284485)